Results 161 to 170 of about 1,442,074 (300)

Proteasome inhibition alleviates proteinuria in Lmx1b knock-in mice with dysfunctional LIM domains. [PDF]

Nat Commun
Hermens J, Lucke L, Pieles O, Maier O, Othmen H, Burghardt T, Schmidt A, Moser M, Madej MG, Schwartz U, Zaparty M, Witzgall R.   +11 more
europepmc   +1 more source

Boosting autophagy in anti-tumor proteasome inhibition-mediated cardiotoxicity. [PDF]

Aging (Albany NY), 2023
Papanagnou ED, Gumeni S, Trougakos IP.
europepmc   +1 more source

Salvianolic Acid a Disrupts the HSP90α‐AKT‐PERK Ternary Complex to Alleviate Atherosclerosis by Activating Endoplasmic Reticulum Stress of Senescent Vascular Smooth Muscle Cells

Advanced Science, EarlyView.
Salvianolic acid A (SAA) selectively induces senescent vascular smooth muscle cell apoptosis, alleviating atherosclerosis. Mechanistically, SAA targets heat shock protein 90 alpha (HSP90α) to disrupt the protein inase B (AKT)‐PRKR‐Like Endoplasmic Reticulum Kinase (PERK) scaffold, driving ubiquitin‐proteasome‐dependent AKT degradation.
Xiuya Guan, Mengkai Lu, Xinhai Cui, Dawei Zhang, Lei Zhang, Lin Lin, Yuan Li, Yuanlong Hu, Chao Li   +8 more
wiley   +1 more source

Proteasome inhibition enhances lysosome-mediated targeted protein degradation. [PDF]

Cell Death Dis
Elshazly AM, Hosseini N, Vangala J, Shen S, Neely V, Hu X, Pagare PP, Harada H, Grant S, Radhakrishnan SK.   +9 more
europepmc   +1 more source

Thrombospondin-1 induction and VEGF reduction by proteasome inhibition. [PDF]

Heliyon, 2023
Bardag-Gorce F, Hoffman C, Meepe I, Ferrini M, Hoft RH, Oliva J, Niihara Y.   +6 more
europepmc   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source

Blm10/PA200-Activated 20S Proteasomes Promote α-Synuclein Degradation and Bypass Proteasome Inhibition in Parkinson's Disease Models. [PDF]

Aging Cell
Ali TT, Zhornyak A, Merghani M, Buschenlange Z, Sakata E, Outeiro TF, Popova B, Braus GH.   +7 more
europepmc   +1 more source

Degrading GPX4 via Biomimetic Nanoparticle‐Mediated In Situ Synthesis of Deep‐Learning‐Designed Binder‐Degron Chimeras for Prostate Cancer Therapy

Advanced Science, EarlyView.
A deep‐learning‐designed binder is fused to a combinatorial degron to create a binder‐degron chimera (bdC) that recruits the CUL2‐RING ubiquitin ligase complex. Encapsulation in a prostate‐cancer‐targeted, CD47‐camouflaged nanocarrier enables tumor‐specific in situ bdC expression, triggering GPX4 degradation and ferroptosis, thereby establishing a ...
Si‐Han Zhang, Ye An, Na Zeng, Mei‐Cheng Liu, Jian‐Xuan Sun, Xi Gong, Jin‐Zhou Xu, Shao‐Gang Wang, Qi‐Dong Xia   +8 more
wiley   +1 more source

Proteasome inhibition as a potential therapeutic target in thymic cancer. [PDF]

Cell Death Dis
Okada S, Benter L, Schrell L, Müller D, Selcen S, Bohnenberger H, Schneider C, Schneider G, Lohrberg M, Koch R, Overbeck TR, von Hammerstein-Equord A, Welter S, Hinterthaner M, Cordes L, Shirneshan K, Netzer C, Inoue M, Marx A, Ströbel P, Küffer S.   +20 more
europepmc   +1 more source

Ηigh-resolution structure of mammalian PI31-20S proteasome complex reveals mechanism of proteasome inhibition. [PDF]

J Biol Chem, 2023
Hsu HC, Wang J, Kjellgren A, Li H, DeMartino GN.   +4 more
europepmc   +1 more source